Last updated: February 25, 2026
What is the Drug?
NDC 43598-0452 corresponds to Alectinib (brand name: Alecensa), an oral ALK (anaplastic lymphoma kinase) inhibitor used primarily for ALK-positive non-small cell lung cancer (NSCLC). Approved by the FDA in 2015, Alectinib targets tumors harboring ALK gene mutations. It is administered as a capsule and indicated for patients previously treated with chemotherapy or crizotinib.
Market Size and Dynamics
Current Market Landscape
- Indication: Treatment of ALK-positive metastatic NSCLC.
- Target Population: Estimated annual incidence of ALK-positive NSCLC in the US is approximately 5,000 to 6,000 cases.
- Competitive Drugs: Crizotinib (first-generation ALK inhibitor), Brigatinib, Lorlatinib, and Ceritinib.
- Market Penetration: Alectinib holds a leading position due to favorable efficacy and safety profile.
Market Trends
- The global NSCLC drug market was valued at USD 12 billion in 2022 and is projected to reach USD 19 billion by 2030.
- ALK inhibitor segment accounts for roughly USD 3 billion of this market.
- Adoption of Alectinib is increasing as physicians favor first-line use based on data from the ALEX trial (2017), which demonstrated superior progression-free survival compared to crizotinib.
Key Market Drivers
- Increasing incidence of NSCLC globally.
- Advances in molecular diagnostics enabling targeted therapy.
- Growing preference for oral targeted therapies over chemotherapy.
- Expanded indications: Alectinib was approved for first-line treatment in 2019.
Regulatory Approvals
- FDA approval (2015) for metastatic ALK-positive NSCLC following progression on or intolerance to crizotinib.
- Approved for first-line therapy in 2019.
- Expanded to include CNS metastases, expanding its market reach.
Price Analysis
Current Pricing
| Region |
Wholesale Acquisition Cost (WAC) per 30-day supply |
Notes |
| United States |
USD 10,000 – USD 12,000 |
Approximate, varies by distributor and pharmacy benefit manager (PBM) negotiations) |
| European Union |
EUR 8,000 – EUR 9,500 |
Prices vary by country and reimbursement policies |
| Japan |
JPY 1,200,000 |
Price set by local regulatory authorities |
Price Trends
- US prices have remained relatively stable since 2019 but face pressure from biosimilars and generics in other regions.
- Price reductions occur in response to increased market competition, especially with next-generation ALK inhibitors.
- Rebate structures and insurance coverage significantly influence net prices in the US.
Future Price Projections
- 2023-2025: Slight decrease in list prices (~2-3%) due to market competition.
- Post-2025: Potential for larger reductions (~10%) if biosimilar or generic versions enter the market.
- Reimbursement Impact: Price adjustments driven by payer negotiations, especially in Europe and Asia.
Price Comparisons With Competitors
| Drug |
30-day WAC |
Indication |
Notes |
| Alectinib (Alecensa) |
USD 10,000 – USD 12,000 |
First-line and second-line ALK-positive NSCLC |
Market leader for first-line treatment |
| Crizotinib (Xalkori) |
USD 9,000 – USD 11,000 |
ALK-positive NSCLC |
Off-patent, generic versions available |
| Lorlatinib |
USD 12,000 – USD 14,000 |
Next-generation ALK inhibitor |
Used after resistance or intolerance |
Competitive Outlook and Future Outlook
- Alectinib's position benefits from superior CNS efficacy and tolerability.
- Future market growth will depend on its approval for earlier lines of therapy and combination regimens.
- The entrance of biosimilars and generics could reduce prices and expand access post-patent expiry, likely around 2027-2028.
- Generics could erode US prices by 20-30%, impacting margins for brand manufacturers.
Key Factors Influencing Market and Price
- Regulatory decisions on expanded indications.
- Clinical trial outcomes for combination therapies involving Alectinib.
- Patent litigations and exclusivity periods.
- Payer policies favoring cost-effective treatments.
- Price negotiations and rebate structures affecting actual transaction prices.
Summary
Alectinib (NDC 43598-0452) holds a prominent role in the NSCLC targeted therapy segment, driven by clinical efficacy and CNS penetration. The US market is stable with high prices, but long-term declines are foreseeable due to biosimilar entry. The upcoming years will see slight price reductions aligned with market competition, and market expansion depends on regulatory approvals and clinical advancements.
Key Takeaways
- The US market for Alectinib is valued at approximately USD 120 million annually, with steady growth driven by first-line adoption.
- Price points are stable currently but expected to decline 10-20% post-2027 due to biosimilar competition.
- Future market opportunity hinges on expanded indications, combination therapies, and global access.
- Competition from next-generation ALK inhibitors will pressure pricing, especially outside the US.
- Reimbursement policies and regional pricing regulations are critical to net revenue projections.
FAQs
1. When is generic Alectinib expected to enter the market?
Patent expiry is anticipated around 2027-2028, after which biosimilars or generics could reduce prices significantly.
2. What factors influence Alectinib’s price in different regions?
Pricing is influenced by regulatory approvals, reimbursement policies, negotiation power of payers, and regional market competition.
3. How does Alectinib compare to other ALK inhibitors in efficacy?
Alectinib demonstrates superior progression-free survival and CNS penetration compared to crizotinib, making it preferred for first-line therapy.
4. Are there significant off-label uses impacting the market?
Currently, no substantial off-label indications influence Alectinib’s market size; it is primarily used for ALK-positive NSCLC.
5. What are the key developments that could alter market projections?
New clinical trial data, regulatory approvals for expanded indications, biosimilar entry, or pricing policy changes could significantly impact the market.
Sources
- U.S. Food and Drug Administration. (2015). FDA approves Alecensa for ALK-positive NSCLC.
- European Medicines Agency. (2019). Summary of product characteristics: Alecensa.
- IQVIA. (2022). Market Trends in Oncology Drugs.
- GlobalData. (2023). Targeted Therapies in Lung Cancer.
- Wolters Kluwer Pharmacy. (2023). Drug Pricing and Reimbursement Report.
